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Necroptosis is a cellular mechanism of necrotic cell death induced by apoptotic stimuli in the form 
of death domain receptor engagement by their respective ligands under conditions where apoptotic 
execution is prevented. Although it occurs under regulated conditions, necroptotic cell death is 
characterized by the same morphological features as unregulated necrotic death. Here we report 
that necrostatin-1, a previously identified small-molecule inhibitor of necroptosis, is a selective 
allosteric inhibitor of the death domain receptor–associated adaptor kinase RIP1 in vitro. We show 
that RIP1 is the primary cellular target responsible for the antinecroptosis activity of necrostatin-1. 
In addition, we show that two other necrostatins, necrostatin-3 and necrostatin-5, also target the 
RIP1 kinase step in the necroptosis pathway, but through mechanisms distinct from that of 
necrostatin-1. Overall, our data establish necrostatins as the first-in-class inhibitors of RIP1 kinase, 
the key upstream kinase involved in the activation of necroptosis.
Apoptosis, a genetically encoded and highly regulated pathway of cell death, plays an 
important role in the normal development of multi-cellular eukaryotes and in the 
maintenance of adult organism homeostasis1. However, it has also become increasingly clear 
that cells have alternative means to trigger regulated cell death, thereby allowing elimination 
of damaged or inappropriately stimulated cells even in the absence of functional apoptosis. 
Mutant mice that are deficient in key apoptotic factors (for example, members of the caspase 
or Bcl-2 families), while exhibiting certain developmental abnormalities, are still able to 
survive to adulthood2,3. Furthermore, certain well-characterized developmental cell death 
events (for example, interdigital tissue elimination4 or motor neuron cell death5) occur 
normally under these apoptosis-deficient conditions with a distinct non-apoptotic 
morphology. Importantly, activation of non-apoptotic cell death has been observed in diverse 
animal models of human pathologies, such as neonatal brain hypoxia6, acute pancreatitis7 
and multiple organ failure8, further establishing the importance of determining molecular 
mechanisms of non-apoptotic cell death. Multiple types of non-apoptotic cell death have 
been described in the literature, including autophagic cell death, necroptosis, aponecrosis 
and paraptosis; however, the underlying molecular mechanisms of these processes are just 
beginning to emerge.
Necroptosis is a notable example of non-apoptotic cell death. It is triggered by the same 
stimuli that normally activate apoptosis, which underscores the notion that it is a regulated 
process of cell death. However, necroptosis is clearly distinct from apoptosis, as it does not 
involve key apoptosis regulators such as caspases and Bcl-2 family members, or cytochrome 
c release from mitochondria9. Furthermore, the cell morphology of necroptotic demise, 
including early loss of plasma membrane integrity, lack of nuclear fragmentation, 
mitochondrial dysfunction and oxidative stress, is very similar to that of necrosis. Notably, 
cell death with necrotic features is prevalent in an array of acute human pathologies, 
including myocardial infarction, cerebral ischemia and acute organ failure. However, 
inhibition of necrosis is not currently perceived as a viable therapeutic strategy because 
necrosis is believed to be an unregulated process caused by overwhelming external stress. As 
“apoptotic” stimuli, now found to also trigger programmed necrosis, are well established as 
contributing to many instances of pathologic injury1, the discovery of necroptosis offers the 
possibility that a subset of pathologic necrotic cell death is regulated by a distinct cellular 
mechanism, and therefore is amenable to therapeutic intervention.
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Important insights into the signaling mechanism of regulated necrosis have been recently 
reported. Serine/threonine kinase activity of the death domain receptor (DR)-associated 
molecule RIP1 was found to be essential for Fas ligand–induced and tumor necrosis factor-α 
(TNFα)-induced necrosis in Jurkat cells10. However, the mechanism that is responsible for 
the execution of necroptosis is not yet clear. We have previously reported the identification 
of a potent and selective inhibitor of necroptosis, necrostatin-1 (Nec-1, 1), which efficiently 
suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types9. 
Furthermore, we and others have found that Nec-1–inhibitable non-apoptotic death is an 
important contributor to pathologic injury in mouse models of cerebral ischemia9 and 
myocardial infarction11. The target of Nec-1 therefore represents a critical mediator in the 
necroptosis pathway that is relevant to regulation of pathologic necrosis.
In the present study, we explored the mechanism of action of Nec-1 and other necrostatins. 
We report that three structurally distinct necrostatins—necrostatin-1, necrostatin-3 (Nec-3, 
2) and necrostatin-5 (Nec-5, 3)—all inhibit RIP1 kinase activity, thereby highlighting the 
role of this molecule as a key step in the necroptosis pathway. Furthermore, we present 
initial analysis of the mechanism of action of three necrostatins that suggests distinct modes 
of RIP1 inhibition. Overall, these data establish RIP1 kinase as a new target for therapeutic 
drug development for human diseases involving necrotic tissue injury, and they establish 
necrostatins as first-in-class potent and selective inhibitors of RIP1 kinase.
Results
Nec-1 is a RIP1 kinase inhibitor in vitro
Our previous analysis9 showed that 1 is capable of inhibiting necroptosis triggered by 
dimerization of the RIP1 kinase domain, which suggests that Nec-1 exerts its activity at or 
downstream from the step of RIP1 kinase activation. Furthermore, because indoles similar to 
1 (Fig. 1a) are a common structural feature in kinase inhibitors (for example, the CDK2 
inhibitor SU9516 (4)12), we considered the possibility that 1 may directly inhibit RIP1 
kinase activity. Though no direct RIP1 kinase substrate has been thus far identified, previous 
studies have suggested13 that RIP1 can autophosphorylate based on incorporation of 
radioactive phosphate in an in vitro kinase reaction using overexpressed and 
immunoprecipitated RIP1. We first sought to confirm that phosphorylation of RIP1 in this 
assay results from its own kinase activity and is not due to other associated kinases. Indeed, 
we observed robust phosphorylation of overexpressed wild type, but not the kinase-inactive 
K45M mutant of RIP1 (Fig. 1b).
Using this assay, we next tested whether RIP1 kinase activity might be inhibited in the 
presence of 1. Indeed, 1 efficiently inhibited kinase activity of overexpressed protein (Fig. 
1c) in a dose-dependent manner. To establish the specificity of 1, we took advantage of the 
very specific structure-activity relationship (SAR) of 1 established in the cellular necroptosis 
assays9. For example, we previously found that elimination of a single methyl group (5, Fig. 
1a) results in only marginal antinecroptotic activity9. Compound 5 was similarly much less 
active in the in vitro RIP1 kinase assay (Fig. 1d). Next, we determined that endogenous 
RIP1, immunoprecipitated from Jurkat cells, also displays activity in the in vitro kinase 
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assay (Fig. 1e). Similar to the results with overexpressed protein, 1 (but not 5) efficiently 
suppressed endogenous RIP1 kinase activity (Fig. 1e). These results show that 1 can inhibit 
RIP1 kinase in vitro, and this activity correlates with 1's ability to inhibit necroptotic cell 
death.
To further verify this conclusion, we again took advantage of the extensive SAR for 1 from 
the cellular assay (Fig. 2a and ref. 14). We selected three additional analogs (6–8) differing 
from 1 by the addition of a single methyl group at various positions. All three compounds 
showed substantially reduced antinecroptotic activity and were likewise ineffective at 
inhibiting RIP1 kinase activity in vitro (Fig. 2b). At the same time, we previously 
determined that of all the positions on 1, only replacement of the sulfur of the thiohydantoin 
with oxygen (as in 9) or changes to the 7 position of the indole ring (for example, addition of 
chlorine as in 10) retain cellular necroptotic inhibitory activity14. Both of these derivatives 
were also active in the in vitro kinase assay (Fig. 2c). Finally, we previously reported that the 
(R)-7-chloromethylhydantoin-Trp ((R)-7-Cl-MH-Trp or (R)-7-Cl-O-Nec-1, 11, 
Supplementary Fig. 1 online) analog of 1 is ∼10-fold more active in the cell-based 
necroptosis assay than the original molecule14. Similarly, this molecule was also 
substantially more active in the in vitro kinase assay (effector concentration for half-
maximum response (EC50) = 182 nM for 1 against endogenous RIP1 from Jurkat cells 
versus EC50 = 18 nM for 11, Supplementary Fig. 1). Overall, these data show that the Nec-1 
SAR perfectly translates from the cellular activity to the in vitro inhibition of RIP1 kinase 
activity, thereby further supporting the notion that inhibition of RIP1 kinase may be the key 
to inhibition of necroptosis in cells by 1.
To characterize the mechanism of RIP1 kinase inhibition, we first determined whether 1 acts 
through an ATP-competitive mechanism. We performed RIP1 kinase assay in the presence 
of increasing concentrations of nonradioactive ATP. Indeed, increasing amounts of cold ATP 
resulted in decreased incorporation of the radioactive phosphate and suppression of the 
inhibitory effect by 1, which is consistent with an ATP-competitive mechanism of inhibition 
by 1 (Supplementary Fig. 2a online).
To establish that 1 exerts its inhibitory effect directly on RIP1, we purified recombinant 
baculovirally expressed human RIP1 from Sf9 cells (Supplementary Fig. 2b). Compound 1 
efficiently inhibited the activity of recombinant RIP1 in the in vitro kinase reaction (Fig. 2d), 
which suggests a direct inhibitory effect of 1 on RIP1, whereas 5 again showed no effect 
(Fig. 2e).
Finally, to verify the specificity of 1 activity, we analyzed whether 1 might inhibit the 
activity of RIP2 (also known as RICK), the closest homolog of RIP1 (33% sequence identity 
in the kinase domain, determined using the TCoffee alignment algorithm from http://
www.tcoffee.org), using the same in vitro autophosphorylation assay. Compound 1 had no 
effect on RIP2 autophosphorylation (Supplementary Fig. 2c), even though it was expressed 
at a level comparable to that of RIP1. At the same time, autophosphorylation of RIP2 was 
inhibited by PD169316 (12, Supplementary Fig. 2d) as previously reported15. In a similar 
experiment, we also determined that 1 does not affect the activity of RIP3 (Supplementary 
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Fig. 2e), another closely related RIP1 homolog (33% identity in the kinase domain), which 
suggests that 1 specifically inhibits RIP1.
Identification of RIP1 autophosphorylation sites
To characterize the mechanism of RIP1 autophosphorylation, we determined residues 
phosphorylated during the kinase assay. We expressed FLAG-tagged human RIP1 in 293T 
cells and immunoprecipitated it using anti-FLAG M2 antibody beads. Before and after the 
kinase reaction, we subjected the samples to SDS-PAGE. We performed phosphorylation 
analysis by in-gel digestion of RIP1, followed by enrichment on immobilized metal affinity 
chromatography (IMAC) resin16,17 and mass spectrometry analysis of the resulting 
phosphopeptides. To maximize the coverage of RIP1, we digested RIP1 protein band 
extracted from the gel independently using three proteases (trypsin, chymotrypsin and Glu-
C), providing almost complete (90.2%) coverage of the RIP1 molecule. This analysis 
identified a number of phosphorylated residues. We found some of these sites, notably 
Ser14/15 (it should be noted that phosphorylation of adjacent sites cannot be reliably 
distinguished by mass spectrometry), Ser20, Ser161 and Ser166 (Supplementary Fig. 3a 
online), phosphorylated only in the samples subjected to the kinase reaction. Thus, they may 
represent RIP1 autophosphorylation sites. On the other hand, we found several other 
residues (Ser6, Ser25, Ser303, Ser320, Ser330/331 and Ser333) to be phosphorylated even in 
the absence of the kinase reaction. Importantly, we found that the kinase-inactive K45M 
RIP1 mutant was unable to phosphorylate a subset of the above-described phosphorylation 
sites in an in vitro kinase assay (Ser14/15, Ser20, Ser161 and Ser166), while retaining other 
phosphorylation events. These data suggest that Ser14/15, Ser20, Ser161 and Ser166 
represent autophosphorylation sites in vitro, detected in the RIP1 kinase assay (Fig. 1), 
whereas Ser6, Ser25, Ser303, Ser320, Ser330/331 and Ser333 are likely to have been 
phosphorylated in the cells before immunoprecipitation, independent of RIP1 kinase activity. 
Notably, while RIP1 (671 amino acids) contains 86 evenly distributed Ser/Thr residues, all 
of the detected autophosphorylation sites are located in the N-terminal kinase domain 
(Supplementary Fig. 3b), which suggests that phosphorylation may regulate the kinase 
activity.
RIP1 T-loop controls inhibition by Nec-1
Analysis of RIP1 against the global human kinase alignment (http://cellsignaling.lanl.gov/
structure/kinase/kinase.html0) suggests that the activation segment (T-loop) of RIP1 is very 
similar to that of B-RAF (ref. 18) (Fig. 3a). In particular, the RIP1 Ser161 
autophosphorylation site corresponds to the Thr598 autophosphorylation site of B-RAF, 
which has been shown to be important for the regulation of the catalytic activity of B-RAF 
(ref. 19). The activation segment is an important regulatory element, controlling kinase 
activity by occluding the catalytic cleft of the kinase (the “closed form”). This inhibition can 
be relieved by destabilization of the “closed” T-loop conformation through a number of 
mechanisms, including (i) phosphorylation within the activation segment, for example, 
autophosphorylation of Thr598 in B-RAF (ref. 19) or phosphorylation of Thr160 in CDK2 
by CAK (ref. 20); (ii) mutations within the activation segment, for example, oncogenic 
mutation V599E in B-RAF (ref. 18); and (iii) allosteric regulation affecting the 
conformation of the T-loop, for example, induced by cyclin A binding to CDK2 (ref. 21). 
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Homology modeling (Fig. 3b) showed that RIP1 can assume a conformation very similar to 
that of B-RAF, which suggests a potential role of Ser161 phosphorylation in the regulation 
of RIP1 kinase activity. Indeed, the S161A RIP1 mutant was substantially less active in the 
in vitro autophosphorylation assay compared with wild-type kinase (Fig. 3c). Because 
Ser161 also serves as one of the acceptors of radioactive phosphate in autophosphorylation, 
we must consider the possibility that the reduction of autophosphorylation in the S161A 
mutant might be due to the loss of a phosphorylation site, rather than the kinase activity per 
se. However, because the S161E mutant did not show a significant decrease in 
autophosphorylation (Fig. 3d), we interpret these data to suggest that the S161A mutation 
indeed decreases RIP1 kinase activity and that Ser161 autophosphorylation positively 
contributes to RIP1 kinase activity. Consistent with this conclusion, the decrease in the 
kinase activity of the S161A mutant translated into 40% attenuation in necroptosis induction 
in Jurkat cells (Fig. 3e). However, mutation of Ser161 did not result in a complete loss of 
activity, which suggests that other important inputs contribute to RIP1 kinase activation 
during necroptosis in the cells, promoting either RIP1 kinase activity or substrate 
availability.
Curiously, the S161A mutation also reduced the degree of RIP1 kinase inhibition by 1 in 
vitro and in cells (Fig. 3d,e), which suggests that the inhibition demonstrated by 1 may be 
related to the structure and/or function of the T-loop. To further explore this hypothesis, we 
tested mutations that are predicted to destabilize the “closed” conformation of the T-loop 
(that is, S161E and F162E), thereby promoting an “open” conformation. These mutations 
are based on structurally equivalent activating mutants of B-RAF (T598D and V599E)18,19. 
Consistent with our hypothesis, the S161E mutant was fully active in vitro, unlike the 
S161A mutant, and furthermore, it was no longer sensitive to inhibition by 1 (Fig. 3d). RIP1-
deficient Jurkat cells are completely insensitive to necroptotic death triggered by Fas, 
cycloheximide and benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk, 13) 
(ref. 10 and Supplementary Fig. 4a online). Introducing wild-type RIP1 kinase into RIP1-
deficient Jurkat cells restores necroptotic cell death, inhibitable by 1 (Fig. 3e). Introduction 
of the S161E mutant into these cells also fully restored induction of necroptosis, which is 
consistent with its full kinase activity in vitro, and, importantly, 1 was no longer capable of 
inhibiting necroptotic cell death mediated by this mutant, which is consistent with its 
resistance to inhibition by 1 in vitro (Fig. 3e). We obtained the same results with the second 
T-loop mutant, F162E, which was also no longer inhibited by 1 in vitro or in cells (Fig. 3e 
and Supplementary Fig. 4b). Loss of inhibition by 1 of necroptotic cell death mediated by 1-
insensitive RIP1 mutants provides an important functional confirmation that RIP1 kinase is a 
primary cellular target of Nec-1. Notably, none of these mutants induced necroptosis in 
Jurkat cells in the absence of Fas antibody, which suggests that additional inputs from the 
receptor are required.
The results of the RIP1 mutagenesis studies, which suggest the involvement of the activation 
segment of RIP1 in the inhibition by 1, are reminiscent of imatinib's (STI-571, 14) mode of 
Abl kinase inhibition. The crystal structure of the imatinib–Abl complex revealed that the 
inhibitor targets the closed inactive conformation of the kinase22. Similar to our data, 
mutations destabilizing the inactive conformation, such as H396P in the activation loop, 
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have been found to eliminate sensitivity of Bcr-Abl to imatinib23. Therefore, 1 may belong 
to a class of allosteric inhibitors selectively recognizing the adaptive pocket on RIP1, which 
is present in the inactive conformation of the RIP1 kinase. Furthermore, based on the 
attenuation of 1's inhibition in the case of the S161A mutant, we hypothesize that Ser161 
may participate in direct (structurally equivalent to the interaction between the P-loop 
Ser466 and the T-loop Ala587 in the published B-RAF structure (Protein Data Bank code 
1UWH), but in reverse direction) or indirect (through a water-mediated hydrogen bond) 
interactions that partially contribute to stabilization of the closed conformation of RIP1. 
Consistent with this proposal, our molecular model predicts that Ser161 forms a hydrogen 
bond with the backbone of Gly188 (Fig. 3b), which may explain the less efficient inhibition 
of the S161A mutant by 1.
Molecular modeling of the RIP1–Nec-1 complex
To dissect the interaction of 1 with RIP1 kinase further, we established a binding mode 
hypothesis of the most potent analog of 1, compound 11 (Supplementary Fig. 1), with RIP1 
kinase using molecular modeling techniques. Based on the binding mode of the structurally 
related CDK2 inhibitor SU9516 (4) and on the finding that RIP1 kinase inhibition by 1 was 
competitive with ATP (Supplementary Fig. 2a), we hypothesized that 11 binds into the ATP 
pocket. Structural ordering of the DFG motif, which forms a part of the magnesium-binding 
pocket (“DFG-in” state)24, is one of the important conformational transitions leading to 
kinase activation, along with structural changes of the adjacent activation loop. The key 
difference between SU9516 and 11 is that SU9516 binds to the active DFG-in state of 
CDK2, whereas our data indicate that 11 may target the inactive state of RIP1. Notably, 
RIP1 has a DLG (Fig. 3a) rather than a DFG motif (as in CDK2) immediately preceding the 
activation segment, and it has been shown that smaller amino acids in the second position of 
this motif promote formation of the inactive “DLG-out” conformation of kinases24. 
Therefore, we concentrated on modeling 11 into the closed DLG-out state of RIP1 kinase 
and verified that the SAR of 11 is consistent with this conformation of RIP1. Inhibitor 11 
forms two classes of interactions with RIP1 (Fig. 4): on the left, the heteroatoms of the 
hydantoin and indole rings form five hydrogen bonds with hinge residues Glu93, Tyr94, 
Glu96, Lys97 and Asn99, while the hydrophobic indole ring is located in the deep pocket 
formed on the top by Leu23 of the P-loop, on the bottom by Leu143 of the C-terminal 
domain, in the back by the gatekeeper residue Met92 and on the right by Leu157 of the DLG 
motif (Fig. 4). Importantly, our model correctly predicts the preference for the R enantiomer 
over the S enantiomer, which would clash with the hinge of RIP1 (ref. 14). Our model also 
provides a good fit for the available SAR in this series of inhibitors (Fig. 2a)14. In particular, 
the amino groups of the indole ring and the hydantoin moiety are predicted to form multiple 
hydrogen bonds, which explains the loss of activity upon methylation of these moieties. The 
amide carbonyl of the hydantoin ring is postulated to form a hydrogen bond with Asn99, 
which is consistent with the complete loss of activity when it is replaced with a methylene 
(15, Supplementary Fig. 5 online)14. The N-methyl on the hydantoin is highly favored in the 
hydrophobic environment of the Leu23 residue, which explains the decreased activity of 5, 
which lacks this group. According to our model, small substituents in the 7 position of the 
indole ring make contacts with Met92, which is consistent with the increased activity 
displayed by the 7-Me, 7-Cl and 7-Br analogs14. At the same time, larger substituents cannot 
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be accommodated due to steric hindrance, which is indeed observed in the case of the 7-OBn 
derivative14. Substituents on positions 4, 5 and 6 of the indole ring result in the loss of 
necroptosis activity14, which is consistent with their proximity to Leu157 of the DLG motif 
in the inactive, DLG-out conformation (Fig. 4a shows the difference in DLG position 
between DLG-out and DLG-in states).
Other necrostatins also inhibit RIP1 kinase
We have previously reported the identification and SAR analysis of two additional potent 
necrostatins: necrostatin-3 (Nec-3, 2) and necrostatin-5 (Nec-5, 3) (Fig. 5a)25,26. Using RIP1 
kinase assays (described in Fig. 1), we investigated whether these two distinct necrostatins 
also target RIP1 kinase activity. To our surprise, considering that 2 and 3 are structurally 
very different from 1, both molecules potently inhibited RIP1 kinase, immunoprecipitated 
from Jurkat cells (Fig. 5b). Furthermore, their effect was specific, as closely related inactive 
analogs (16 and 17, respectively) lacked activity. Compound 2 also potently inhibited 
recombinant RIP1, expressed in Sf9 cells, whereas (surprisingly) 3 was essentially inactive 
(Fig. 5c). Inhibition of recombinant RIP1 by 2 again correlated with its cellular activity, 
since 16 was much less active (Fig. 5d). Based on these results, we conclude that 2 inhibits 
RIP1 kinase directly, similar to 1. On the other hand, it is likely that 3 acts on RIP1 
indirectly, through interactions with another component present in the endogenous RIP1 
complex, but absent in the recombinant RIP1 sample.
Because inhibitor 2 is structurally different from 1, we explored whether these two 
molecules inhibit RIP1 differently. Indeed, unlike 1, which completely lacks activity against 
the S161E mutant of RIP1, 2 still inhibited the autophosphorylation of this mutant in vitro, 
albeit less effectively than in the case of wild-type RIP1 (Fig. 5e,f). Furthermore, consistent 
with the ability of 2 to inhibit the autophosphorylation of the S161E RIP1 mutant and in 
contrast to that of 1, 2 was capable of inhibiting cellular necroptosis mediated by S161E 
RIP1 (Fig. 5g), though it did so less effectively than in cells expressing wild-type RIP1. We 
are currently pursuing further structural analyses of the interactions of 1 and 2 with RIP1 to 
determine the mechanistic basis for their differential mode of RIP1 inhibition.
Necrostatin inhibition of RIP1 is independent of Hsp90
RIP1 is a client protein of Hsp90 (ref. 27), and geldanamycin (18, a specific ATP-
competitive inhibitor of Hsp90) has been previously reported to inhibit RIP1 kinase-
dependent necroptosis10. To further investigate the mechanistic basis of RIP1 kinase 
inhibition by necrostatins, we explored whether small molecules, in particular 3 acting on 
RIP1 kinase indirectly, might affect RIP1 through the regulation of Hsp90 chaperone (see 
Supplementary Methods online for assay details). However, using the kinase assay lysis 
buffer conditions, we were unable to detect the presence of Hsp90 in either the samples of 
endogenous Jurkat cell RIP1 or human RIP1 expressed in Sf9 cells (Supplementary Fig. 6a 
online). These results suggest that the Hsp90– RIP1 complex is labile and may not tolerate 
immunoprecipitation conditions used for RIP1 kinase assays. Thus, it is unlikely that Hsp90 
is critical for RIP1 kinase activity in vitro, and therefore Hsp90 is unlikely to be the target of 
necrostatins. Consistent with this proposal, geldanamycin did not significantly affect the 
activity of either the endogenous RIP1 or the protein expressed in Sf9 cells (Supplementary 
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Fig. 6b). Furthermore, using an established fluorescence polarization assay28, we found that 
none of the Necs are direct ATP-competitive inhibitors of Hsp90 in Jurkat cell lysates, as 
they failed to disrupt FITC-geldanamycin binding to Hsp90 (Supplementary Fig. 6c). In 
addition, the cellular activity of the Necs is distinguishable from the effect of inhibiting 
Hsp90, as none of the Necs reduced protein levels of RIP1 kinase as is seen with 
geldanamycin27 (Supplementary Fig. 6d). Finally, we found that none of the necrostatins 
significantly inhibit RIP1-Hsp90 interaction (Supplementary Fig. 6e), which was detectable 
using hypotonic cell lysis conditions. Based on these data we conclude that the activity of 
necrostatins is not related to the regulation of Hsp90 activity or its association with RIP1. 
This conclusion is also consistent with the lack of necrostatin effect on NFkB activation 
(Supplementary Fig. 7 online), which is prominently inhibited by geldanamycin27.
Discussion
In summary, we show that all three classes of potent necrostatins identified in a random 
unbiased cell-based screen target RIP1 kinase activity through distinct mechanisms—T-
loop–dependent inhibition of RIP1 kinase by 1, partially T-loop–independent inhibition of 
RIP1 by 2 and indirect inhibition of RIP1 by 3—thus highlighting the critical role of RIP1 
kinase activity for necroptotic cell death. Our discovery that multiple unrelated necrostatins 
isolated in a cell-based assay all target RIP1 kinase is unexpected. Our results demonstrate 
that a key step in the necroptosis pathway (RIP1 kinase activity) is highly amenable to 
small-molecule inhibition. Considering the emerging importance of necroptosis in multiple 
paradigms of pathologic injury in vivo9,11, our results suggest that RIP1 kinase may 
represent a promising new target for drug discovery. Furthermore, high potency and the 
well-explored SAR of identified necrostatins may provide a strong basis for their further 
therapeutic development. Finally, the ability of an unbiased screen to identify potent and 
specific small-molecule inhibitors of a key regulator in a cellular pathway demonstrates the 
power of cell-based screening for small-molecule discovery research.
Our previous analysis suggested that the signaling step, targeted by 1, plays a universally 
important role in multiple cellular paradigms of necroptosis triggered by DR ligands (that is, 
TNFα, Fas ligand and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL, also 
known as Apo2L)) in various primary cells and cell lines of epithelial, fibroblast and 
hematopoietic origin9. These results contrast with the emerging data regarding the cell type 
specificity for the mechanisms of necroptosis execution. For instance, while reactive oxygen 
species (ROS) generation through the formation of the RIP1–Rac1– NADPH oxidase 
complex has been recently proposed to be a key mediator of DR-induced necrotic death in 
mouse fibrosarcoma L929 cells29, neither oxidative stress nor NADPH oxidase activity 
appear to play a role in other paradigms of necroptosis (for example, in Jurkat cells; ref. 9 
and Supplementary Fig. 7a,b). Similarly, autophagy has been proposed to represent a key 
execution mode of necrosis in some cell lines, for example, L929 and human monocytic 
U-937 cells9,30, but it was found to play only a secondary role in other cases, for example, 
mouse embryonic fibroblasts and Jurkat cells9. Therefore, our data identify RIP1 kinase as a 
key universal upstream step in the necroptosis pathway that is potentially followed by 
divergent downstream execution steps, which are dependent on the cellular context. 
Furthermore, our findings identify RIP1 as a specific protein target for various paradigms of 
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pathologic cell death, for which inhibition by 1 has been demonstrated both in vitro and in 
vivo, including in animal models of brain ischemia9 and myocardial infarction11, and in 
death triggered by glutamate31, plant sterols32 and killing of apoptosis-resistant cancer cells 
by the chemotherapeutic agent shikonin33.
RIP1 protein consists of three major domains, which have been linked to distinct activities. 
The C-terminal death domain is important for homologous interaction with death domain 
receptors34 and/or the DR-associated adaptor TRADD (ref. 35). The central region of RIP1 
has been implicated in NFκB activation through polyubiquitination of Lys377 (ref. 36), 
nucleating the formation of NFκB-inducing signaling complex I (refs. 37,38). While RIP1 
was originally reported not to contribute to apoptosis induction in Jurkat cells13, recent 
evidence suggests that it is an intrinsic part of the DR-induced apoptosis signaling complex 
II (DISC)39–41, although the domains required for this activity have not been identified. The 
N-terminal Ser/Thr kinase domain of RIP1 is required for necroptosis10 but is dispensable 
for NFkB activation42 and apoptosis in Jurkat cells10. At the same time, the kinase activity 
was found to be dispensable for NFκB activation42 and apoptosis in Jurkat cells10. 
Consistent with these results, necrostatins showed no effect on NFκB activation 
(Supplementary Fig. 7c,d); we have also not observed attenuation of necroptosis in Jurkat 
cells reconstituted with the K377R mutant of RIP1, which is defective in NFκB signaling36 
(Supplementary Fig. 4a). Similarly, we have not observed any inhibition of apoptosis by 1 in 
multiple cellular systems in which 1 was found to efficiently inhibit necroptosis9. These data 
are consistent with the selective role of RIP1 kinase in necroptotic cell death. Considering 
the potency and selectivity of 1 for inhibiting RIP1 kinase and the complexity of RIP1 
signaling, 1 and its active analogs represent a unique and very useful class of probes for 
RIP1 kinase activity in vitro and in vivo.
Finally, our molecular modeling data presents a feasible model of RIP1 inhibition by Nec-1, 
which will be further validated once the structure of the RIP1 kinase domain becomes 
available. According to our model, the predicted position of Leu157 in its active DLG-in 
conformation is approximately 10 Å away from the predicted binding pose of 11 (Fig. 4a) 
and therefore cannot account for the sharp SAR (Fig. 2a)14 on the 4, 5 and 6 positions of the 
indole ring. This observation further supports the notion that the Nec-1 series of inhibitors 
may target the inactive DLG-out state of RIP1 kinase. The plausible explanation for such 
selectivity, based on our model, may be that the hydrophobic 4, 5 and 6 positions of the 
indole ring would be exposed to solvent in the DLG-in conformation, destabilizing 11 
binding to RIP1. At the same time, the DLG-in conformation would also promote ATP 
binding into RIP1's catalytic center by removing Leu157 of the DLG motif from the ATP 
path, thus promoting competition with 11. It should be also noted that RIP1 appears to have 
substantial activity even in the basal state when isolated from unstimulated Jurkat cells (Fig. 
1e), which is consistent with only partial attenuation of its activity and necroptosis activation 
by S161A mutation (Fig. 3c,e). Based on these data, the modeling results and the inability of 
1 to inhibit T-loop mutants, we propose a plausible model that RIP1 kinase exists in 
equilibrium between inactive DLG-out and active DLG-in conformations, and 1 
preferentially binds to and stabilizes the inactive conformation, thereby shifting the 
equilibrium toward the inactive state. Conversely, T-loop–mediated activation will shift the 
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equilibrium in the opposite direction, potentially functioning to modulate the kinetics of 
necroptosis initiation and/or to render RIP1 kinase activation irreversible. While our current 
study focused primarily on the identification of the cellular target of necrostatins, our 
molecular modeling provides a framework for further analysis of the molecular mechanism 
of RIP1 kinase activation and inhibition, and for future rational design of small-molecule 
inhibitors of RIP1 kinase activity.
Methods
Chemical compounds
All small-molecule inhibitors used in the paper have been previously described. 1 was from 
Sigma. zVAD-fmk (13) was purchased from Axxora. NADPH oxidase inhibitors apocynin 
(19) and diphenyleneiodonium chloride (DPI, 20) were obtained from Cayman Chemical. 
Geldanamycin (18) was purchased from Invivogen. FITC-geldanamycin was from Biomol. 
The synthesis of all necrostatins used in this study has previously been described: 
compounds 5–11 and 15 (refs. 14,43), compounds 2 and 16 (ref. 25) and compounds 3 and 
17 (ref. 26).
Reagents
We purchased human TNFα from Cell Sciences. Mouse RIP1 antibody was from BD 
Biosciences. Rabbit RIP1 agarose-conjugated beads were obtained from Santa Cruz. Protein 
A magnetic beads were purchased from Dynal and covalently coupled to mouse RIP1 
antibody using dimethyl pimelimidate (DMP) reagent (Pierce) according to the standard 
protocol from New England Biolabs. Rat Hsp90 and mouse β-tubulin antibody were 
obtained from Stressgene. We purchased FLAG M2 agarose beads from Sigma and 
glutathione-sepharose from Amersham. Other common reagents and chemicals were 
purchased from Sigma.
Cell lines
Fas-associated via death domain (FADD)-deficient and RIP1-deficient human Jurkat T cells, 
Spodoptera frugiperda Sf9 cells and SV40-transformed human kidney embryonic epithelial 
HEK 293T cells were purchased from ATCC. Jurkat and 293T cells were maintained in 
RPMI1640 or DMEM (Invitrogen), respectively, supplemented with 10% fetal bovine serum 
(Sigma) and antimycotic-antibiotic mix (Invitrogen). Sf9 cells were maintained in SF-900 II 
SFM medium (Invitrogen).
DNA plasmids
Human pcDNA3-FLAG-RIP1 expression vector was a generous gift of J. Tschopp 
(University of Lausanne). RIP1 point mutations were introduced into pcDNA3-FLAG-RIP1 
vector using QuikChange mutagenesis kit (Stratagene). pcDNA3-RIP2-Myc expression 
vector was a generous gift of G. Nunez (University of Michigan). RIP3 complementary 
DNA was amplified by PCR using MGC:75066 EST clone (ATCC) along with FLAG 
sequence, introduced into 5′ primer, and cloned into pcDNA3.1 vector (Invitrogen). RIP1 
baculoviral expression vector was generated by PCR amplification of residues 1–375 of 
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human RIP1, which were subcloned between the EcoRI and PstI sites of the pAcGHLT 
vector, containing GST tag (BD Biosciences).
In vitro kinase assay
The assay was performed essentially as described13. 293T cells were transfected with 
pcDNA3-FLAG-RIP1 vector, vectors encoding RIP1 mutant proteins or pcDNA3-RIP2-Myc 
and pcDNA3-FLAG-RIP3 vectors using standard Ca3(PO4)2 precipitation procedure. 
Culture medium was replaced 6 h after the transfection and cells were lysed 48 h later in the 
TL buffer consisting of 1% Triton X-100, 150 mM NaCI, 20 mM HEPES, pH 7.3, 5 mM 
EDTA, 5 mM NaF, 0.2 mM NaVO3 (ortho) and complete protease inhibitor cocktail 
(Roche). Immunoprecipitation was carried out for 16 h at 4 °C using anti-FLAG M2 agarose 
beads (Sigma), followed by three washes with TL buffer and two washes with 20 mM 
HEPES, pH 7.3. Beads were incubated in 15 μl of the reaction buffer containing 20 mM 
HEPES, pH 7.3, 10 mM MnCl2 and 10 mM MgCl2 for 15 min at 23–25 °C in the presence 
of different concentrations of necrostatins. For these assays, compound stocks (in DMSO) 
were diluted to appropriate concentrations in DMSO before the addition to the reactions to 
maintain final concentration of DMSO for all samples at 3%. Kinase reaction was initiated 
by addition of 10 μM cold ATP and 1 mCi of [γ-32P] ATP, and reactions were carried out for 
30 min at 30 °C. Reactions were stopped by boiling in SDS-PAGE sample buffer and 
subjected to 8% SDS-PAGE. RIP1 band was visualized by analysis in a Storm 8200 
Phosphorimager (Molecular Dynamics). Similar protocol was used for endogenous RIP1 
kinase reactions, except mouse monoclonal RIP1 antibody (BD Biosciences) and protein 
magnetic beads (Dynal) or rabbit RIP1 antibody-coupled agarose beads (Santa Cruz) were 
used. For recombinant baculovirally expressed RIP1, protein was expressed in Sf9 cells 
according to manufacturer's instructions (BaculoGold system, BD Biosciences) and purified 
using glutathione-sepharose beads (Amersham). Protein was eluted in 50 mM Tris-HCl, pH 
8.0 supplemented with 10 mM reduced glutathione, and eluted protein was used in the 
kinase reactions, supplemented with 5 × kinase reaction buffer (100 mM HEPES, pH 7.3, 50 
mM MnCl2, 50 mM MgCl2, 50 μM cold ATP and 5 μCi of [γ-32P]ATP).
RIP1 reconstitution in RIP1-deficient Jurkat cells
For analysis of RIP1 mutants, 5 × 106 RIP1-deficient Jurkat cells were electroporated with 
2.7 μg of pcDNA3-FLAG-RIP1 vectors and 0.3 μg pEGFP vector (Clontech), serving to 
identify transfected cells, using a Nucleofector II device with reagent V (Amaxa). 48 h after 
electroporation, live cells were isolated by centrifugation (1,400 r.p.m., 40 min) over the 
layer of Ficoll-PAQUE (Amersham). Cells were treated with 1 mg ml cycloheximide, 100 
mM zVAD-fmk and 200 ng ml−1 agonistic Fas antibody (clone 7C11, Beckman Coulter) for 
24 h and stained with 2 μg ml−1 propidium iodide (Roche). Percentages of green fluorescent 
protein (GFP)-positive and propidium iodide–negative cells were determined using FACS 
(FACSCalibur, BD Biosciences) at Tufts Flow Cytometry Core Facility.
Cellular EC50 determination of necrostatins
Determination of EC50 was performed in FADD-deficient Jurkat cells treated with human 
TNFα as previously described14. Briefly, cells were seeded into 96-well plates and treated 
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with a range of necrostatin concentrations (30 nM to 100 μM, 11 dose points) in the 
presence and absence of 10 ng ml–1 human TNFα for 24 h. For these and all other cellular 
assays, compound stocks (in DMSO) were diluted to appropriate concentrations in DMSO 
before addition to the cells to maintain final concentration of DMSO for all samples at 0.5%. 
Cell viability was determined using CellTiter-Glo luminescent cell viability assay 
(Promega). Ratio of luminescence in compound and TNF-treated wells to compound-treated, 
TNF-untreated wells was calculated (viability, %) and used to calculate EC50 by nonlinear 
regression in GraphPad Prizm.
Mass spectrometry analysis of RIP1 autophosphorylation sites
HEK 293T cells (two 15 cm2 plates) were transfected with 20 mg of pcDNA3-FALG-RIP1 
vector as described above. 48 h after transfection, cells were lysed and immunoprecipitated 
using anti-FLAG M2 antibody beads as described above. Samples were eluted using 
modified SDS sample buffer (70 mM Tris-HCl, pH 8.1, 2% SDS, 5 mM DTT, bromphenol 
blue) by boiling for 5 min at 95 °C. Free thiols were alkylated using 13 mM iodoacetamide 
(30 min in the dark). Excess of iodoacetamide was quenched by addition of 5 mM DTT for 
10 min. Samples were separated by 8% SDS-PAGE, and RIP1 band was visualized by 
staining with GelCode Blue reagent (Pierce). In-gel digestion of RIP1 band, IMAC 
purification, LC-MS/MS and data analysis were performed as previously described44.
Molecular modeling of RIP1 and RIP1–11 complex
Homology model of RIP1 kinase domain was built with MODELER45 using the structure of 
B-RAF (ref. 18) as template. The homology model was minimized in CHARMm46, and the 
conformation of the side chains was predicted by the SCWRL3 algorithm (http://
dunbrack.fccc.edu/SCWRL3.php). For modeling of the RIP1–11 complex, the indole ring 11 
was initially placed in the area occupied by the indole ring of SU9516 in CDK2. The 
subsequent extensive refinement of this complex was carried out in CHARMm46. The 
models were analyzed using PyMOL visualization software (http://pymol.sourceforge.net).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Nec-1 (1) is an inhibitor of RIP1 kinase. (a) Structures of 1 and 5. EC50 values for inhibition 
of cellular necrosis in TNFα-treated FADD-deficient Jurkat cells were determined as 
described in the Methods and were previously reported14. (b) Phosphorylation of RIP1 
requires its kinase activity. Expression constructs of FLAG-tagged wild-type (WT) or a 
kinase-inactive point mutant of RIP1 (K45M) were transfected into 293T cells and RIP1 
kinase assay was performed as described in the Methods in the presence of [γ-32P]ATP for 
30 min at 30 °C. Samples were subjected to SDS-PAGE and RIP1 band was visualized by 
autoradiography. Relative intensities of radioactive bands were quantified and are shown 
(ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads 
was subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein 
amounts in kinase reactions. (c) 1 inhibits the autophosphorylation of overexpressed RIP1 in 
vitro in a dose-dependent fashion. Assay was performed as in b, except different amounts of 
1 were added 15 min before ATP. (d) Inactive analog of 1 (5) displays substantially reduced 
activity against RIP1 kinase in vitro. Assay was performed as in c with indicated 
concentrations of 1 and 5. (e) 1 inhibits the autophosphorylation of endogenous RIP1 in 
vitro. RIP1 was immunoprecipitated from lysates of WT and RIP1-deficient Jurkat cells 
using agarose-conjugated anti-RIP1 antibody, and kinase reactions were performed as in c in 
the presence of the indicated amounts of 1 or 5. Assays were performed at least two or three 
times, and similar results were obtained each time. The representative images are shown.
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Figure 2. 
SAR analysis of RIP1 inhibition by necrostatins. (a) Summary of cellular SAR of 1 based on 
ref. 14. (b,c) In vitro activity of select inactive (b) and active (c) 1 analogs. Endogenous 
RIP1 kinase assays were performed as in Figure 1e in the presence of indicated amounts of 1 
analogs. Structures of the derivatives are shown. EC50 values for inhibition of cellular 
necrosis in TNFα-treated FADD-deficient Jurkat cells by necrostatins were determined as 
described in the Methods and were previously reported14. (d,e) 1 inhibits kinase activity of 
recombinant RIP1 expressed in Sf9 cells. Recombinant RIP1, expressed in Sf9 cells, was 
subjected to in vitro kinase assay in the presence of indicated amounts (d) or 100 μM (e) of 
1 (d,e) or 5 (e). Assays were performed at least two or three times, and similar results were 
obtained each time. The representative images are shown.
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Figure 3. 
Effect of Ser161 and Phe162 mutations on necroptosis and inhibition by 1. (a) Sequence 
alignment of the magnesium binding and activation segments of B-RAF and RIP1. Thr598 
of B-RAF and Ser161 of RIP1 are shown in red. Kinase-conserved DFG motif is underlined. 
(b) Homology model of RIP1. (c,d) S161A (c) and S161E (d) mutations attenuate RIP1 
kinase sensitivity to 1 in vitro. Kinase assays of RIP1 mutants overexpressed in 293T cells 
were performed as described in Figure 1. “–” indicates DMSO. In parallel to kinase 
reactions, a sample of beads was subjected to western blot analysis using anti-RIP1 antibody 
to ensure equal protein amounts in kinase reactions. Assays were performed at least two or 
three times, and similar results were obtained each time. The representative images are 
shown. (e) Mutations of Ser161 and Phe162 attenuate inhibition of necroptosis by 1. 
Corresponding pcDNA-FLAG-RIP1 vectors were transiently electroporated into RIP1-
deficient Jurkat cells along with pEGFP. Cells were allowed to recover for 48 h, treated with 
anti-FAS antibody, cycloheximide and zVAD-fmk to induce necroptosis and 30 μM 1, 
followed by analysis by FACS as described in the Methods. The data were obtained in a 
single experiment performed in triplicate and represent mean values ± s.d. Experiment was 
repeated multiple times, and similar results were obtained each time. Equal expression of 
RIP1 mutants was confirmed by western blot using anti-RIP1 and anti-tubulin antibodies.
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Figure 4. 
Molecular model of the RIP1–11 complex. (a) RIP1 is shown in ribbon representation with 
the binding site amino acids shown in wireframe representation, and with the gatekeeper 
residue and 11 shown in stick representation. Solid surfaces of DLG leucine in its predicted 
DFG-in and DFG-out conformations are highlighted in purple and brown, respectively. (b) 
RIP1 is shown in ribbon representation with the binding site solid surface displayed, and 11 
is shown in spacefill representation. (c) RIP1 is shown in ribbon representation with the 
binding site transparent surface displayed, and binding site amino acids and 11 are shown in 
stick representation. Different structural features of RIP1 kinase are shown in different 
colors and are annotated on the included text panel.
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Figure 5. 
Necrostatin-3 and necrostatin-5 inhibit RIP1 kinase activity. (a) Structures of necrostatin-3 
and necrostatin-5 analogs. Cellular EC50 in TNFα-treated FADD-deficient Jurkat cells are 
shown. (b) Additional Necs inhibit activity of Jurkat cell RIP1. In vitro kinase reaction in the 
presence of the indicated concentrations of necrostatins was performed as in Figure 1e. (c,d) 
2, but not 16, specifically inhibits recombinant RIP1 kinase, expressed in Sf9 cells. In vitro 
kinase reactions in the presence of the indicated concentrations of necrostatins were 
performed as in Figure 2d. (e,f) 2 still inhibits activity of S161E mutant of RIP1 in vitro. WT 
FLAG-RIP1 (e) and S161E FLAG-RIP1 (f) were expressed in 293T cells and subjected to in 
vitro kinase assay in the presence of the indicated concentrations of necrostatins as in Figure 
1c. Assays were performed at least two or three times, and similar results were obtained 
each time. The representative images are shown. (g) 2 attenuates necroptosis mediated by 
S161E mutant of RIP1. Recapitulation of WT and S161E mutants in RIP-deficient Jurkat 
cells and necroptosis viability assay were performed as described in Figure 3e. Compounds 
were used at 30 μM. The data were obtained in a single experiment performed in triplicate 
and represent mean values ± s.d. Experiment was repeated multiple times, and similar results 
were obtained each time. Equal expression of RIP1 mutants was confirmed by western blot 
using anti-RIP1 and anti-tubulin antibodies.
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